John B. Reiss, Partner and Co-Chair of the Health Law Practice Group in the Philadelphia office, co-wrote this article for Update, a bi-monthly magazine associated with the Food and Drug Law Institute.

In this article, Mr. Reiss examine several legal issues facing the medical device, pharmaceutical, and biologies industries using court decisions or settlements over the past year as examples. They conclude that to avoid high exposure to liability, companies need an aggressive corporate compliance plan that establishes a culture of compliance throughout the array of activities undertaken by those companies.

To read the full article, click the link below.